BRTX
BioRestorative Therapies Inc

3,457
Mkt Cap
$13.59M
Volume
15,152.00
52W High
$2.55
52W Low
$1.19
PE Ratio
-1.20
BRTX Fundamentals
Price
$1.57
Prev Close
$1.58
Open
$1.58
50D MA
$1.56
Beta
1.12
Avg. Volume
52,782.67
EPS (Annual)
-$1.16
P/B
2.59
Rev/Employee
$36,454.54
Loading...
Loading...
News
all
press releases
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·30d ago
News Placeholder
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +26.83% and +51.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks·5mo ago
News Placeholder
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Zacks·6mo ago
News Placeholder
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago
News Placeholder
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function
BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients. read more...
Benzinga·1y ago

Latest BRTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.